ModernaTX, Inc. is advancing its mRNA-1647 cytomegalovirus vaccine through a Phase 2 clinical trial, focusing on both CMV-seronegative and CMV-seropositive healthy adults aged 18-40. The vaccine's potential to prevent CMV infections, particularly in vulnerable populations such as pregnant women, positions it strategically within the growing vaccine market. Given the increasing prevalence of CMV and the lack of approved vaccines, successful outcomes could lead to significant market opportunities. Competitive analysis indicates that while several companies are exploring CMV vaccines, Moderna's mRNA platform offers a unique technological advantage. Diligence should focus on the trial's safety and immunogenicity data, as well as the regulatory landscape for CMV vaccines.